Risk factors for the development of donor‐specific antibodies after pediatric heart transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1399-3046|19|8|906-910

ISSN： 1397-3142

Source： PEDIATRIC TRANSPLANTATION, Vol.19, Iss.8, 2015-12, pp. : 906-910

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donor‐specific anti‐HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical impact of preformed donor‐specific denatured class I HLA antibodies after kidney transplantation

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 5, 2015-05 ,pp. : 393-402

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early immunosuppression treatment correlates with later de novo donor‐specific antibody development after kidney and pancreas transplantation

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1119-1127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation

By  

PEDIATRIC TRANSPLANTATION, Vol. 19, Iss. 8, 2015-12 ,pp. : 896-905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of early treatment for de novo donor‐specific antibodies in pediatric kidney transplant recipients in a cross‐sectional and longitudinal cohort

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite